Back to TEVA
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
Upcoming Catalysts
What are catalysts?12mo
rasagiline mesylate 1.0 mg Patent Expiration
rasagiline mesylate 1.0 mg
Aug 27ConfirmedSTALE
SourceCompetitive Landscape
Drug Information
Patent & Exclusivity
Regulatory Approvals
EMA4/4/2016
Rasagiline Viatris (previously Rasagiline Mylan)
Rasagiline Viatris is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
View on EMAEMA1/12/2015
Rasagiline ratiopharm
Rasagiline ratiopharm is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts